Dornase Alfa

Overview

Dornase Alfa is an enzyme, acts as a mucolytic, used through inhalation to assist the clearance of bronchial secretions in patients with cystic fibrosis. Chemically, Dornase Alfa is recombinant human deoxyribonuclease (rh-DNase) produced by genetic engeering. It acts as a mucolytichydrolyzes extracellular DNA that has accumulatedin sputum from decaying neutrophils. The exact mechanism of hydrolysis is unknown, but by cleaving extracellular DNA, it decreases the viscosity of the sputum which then improves mucociliary clearance of sputum. It also reduces the incidence of recurrent bacterial infections. Clinical trials report that patients given it have an increase in general perception of well-being and a decreased perception of dyspnea, frequency of cough and chest congestion. It was approved for use by the FDA in December 1993.

Categories

Primary Characterstics

Indications

Back to top

Pharmacokinetics

Back to top

Contraindications

Back to top

Drug Interactions

Back to top

Side Effects

Back to top

Dosage

Dornase Alfa's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

2500 mg2500 (2500)24 hourlyInh1 or over 21 years may benefit forms twice daily dosage. By inhalation of nebulised solution (by jet nebulised)

Paedriatic Dosage (20kg)

2.5 mg2.5 (2.5)24 hourlyInh1 or over 21 years may benefit forms twice daily dosage. Child over 5year by inhalation of nebulised

Neonatal Dosage (3kg)

No data regarding the neonatal dosage details of Dornase Alfa is available.

High Risk Groups

Back to top

Warning / Precautions

Back to top

Storage Conditions

Back to top

Interference in Pathology

Back to top

Brands / Trade Names of Dornase Alfa

Back to top

Manufacturers of Dornase Alfa in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages